Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li><keyword id="3658" type="General" weightage="100" keywordseo="india" source="Orion">India</keyword> is likely to reduce the gap between the second dose and the <keyword id="2825536" type="General" weightage="20" keywordseo="Booster-dose" source="Orion">booster dose</keyword> from nine months to six months.</li><li>This decision might come soon for people travelling abroad as countries have started mandating a third dose.</li><li>Health experts have also said that reducing the gap between both the doses will also help in speeding up the booster dose drive in the country.</li></ul>India is reportedly considering allowing people who are travelling abroad to get their booster doses early i.e before completing nine months of gap between the second and booster dose of COVID-19. According to a <a href="https://www.hindustantimes.com/india-news/covid19-some-outbound-flyers-may-be-able-to-get-boosters-early-101651714101322.html">report</a> by Hindustan Times, the gap between second dose and booster dose may be reduced to six months from nine months. The <keyword id="46535" type="General" weightage="80" keywordseo="health-ministry" source="Orion">Health ministry</keyword> may set out this new rule keeping in mind the countries requiring travellers to have been administered a third shot of the COVID-19 vaccine. According to the report, several people have appealed to the central government lately to reduce the gap because many countries have started mandating a third dose for international travellers travelling for jobs, education, or business. Also, many health experts have also said that reducing the gap between both the doses will also help in speeding up the booster dose drive in the country. According to the data by the Health Ministry, around 105 billion people were eligible for a booster shot, as of May 1, 2022, however, only 28.3 million people have only taken it. “The National Technical Advisory Group on Immunisation (NTAGI) is looking at the data to see if it is good to reduce the gap from existing nine months. They might prioritise those who urgently need a booster for the purpose of travel as many countries have made it a requirement for travel. However, the ultimate decision will be based on the opinion of experts on the technical panel,” told a senior government official to HT in case of anonymity. One of the other reasons behind this is that reducing the gap will also help in bringing down the number of vaccine wastage and reduced immunity in people. Due to lack of people to administer, the number of vaccine wastage is increasing. Several studies have suggested that the level of antibody declines over time in the vaccinated population, which shows an urgent need for booster shots to protect the people from getting infected. NTAGI members, on Wednesday, had a discussion on reducing the gap between second dose and the booster dose and opening up the vaccination drive for children below the age of 11 years. However, no final decision was taken by the body on both the matters. India started the booster dose vaccination drive for healthline workers and <a href="https://www.businessinsider.in/india/news/booster-shots-against-covid-19-for-all-adults-to-be-available-from-april-10/articleshow/90728511.cms">people aged above 60 years</a> from January 10, 2022. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/enterprise/news/cognizants-latest-earnings-have-a-silver-lining-for-indian-it-majors-tcs-infosys-and-wipro/articleshow/91334290.cms">Cognizant’s latest earnings have a silver lining for Indian IT majors TCS, Infosys and Wipro</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/second-day-to-subscribe-to-lic-ipo-post-poor-demand-on-day-1-and-gmp-falls-to-65/articleshow/91324706.cms">LIC IPO: Second day to subscribe to the issue post poor demand on Day 1; GMP falls to ₹65</a>

India may consider reducing the gap between second dose and the booster dose of COVID-19 for those travelling abroad

The analysis of the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech is still being conducted by regulator Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee and their next meeting will be held on January 1. The Subject Expert Committee met on Wednesday to consider the Emergency Use Authorisation (EUA) request of Pfizer, SII and Bharat Biotech Private Ltd. Further time was requested on behalf of Pfizer, while the additional data and information presented by the SII and Bharat Biotech was perused and analysed by the SEC. "The analysis of the additional data and information is going on. SEC will convene again on 1st January 2021 (Friday)," the Centre said in a statement. America's Pfizer was the first one to apply for the accelarated approval on December 4, followed by the SII and Bharat Biotech who applied on December 6 and 7, respectively. On December 9, the Subject Expert Committee had asked the SII and Bharat Biotech to submit more data and information to get approval. The expert panel had then recommended the SII to submit outcome of the assessment of UK regulatoe for grant of emergency use approval, the updated safety data of the Phase 2/3 clinical trial and immunogenicity data from the clinical trials in UK and India. Bharat Biotech was recommended to present the safety and efficacy data from the ongoing Phase 3 clinical trial in the country for further consideration. Their applications were reviewed again earlier on Wednesday, hours after the UK accepted the recommendation of the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use. The authorization was significant for India as the Pune-based SII had tied up with the company to conduct clinical trials and manufacture the vaccine. Besides, Bharat Biotech is developing country's indigenous coronavirus vaccine - Covaxin - in collaboration with the Indian Council of Medical Research. The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with 2 crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with co-morbidities. Covishield uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the coronavirus if it later infects the body. The vaccine can be stored, transported and handled at normal refrigerated conditions at two to eight degrees Celsius for at least six months and administered within existing healthcare settings. Its interim analysis for efficacy showed that the vaccine was 70.4 per cent effective at preventing symptomatic COVID-19 occurring more than 14 days after receiving two doses of the vaccine. The SII has already made 40 to 50 million doses of the shot. "We have 40-50 million doses of Covishield stockpiled. We will be producing around 300 million doses by July 2021," its CEO Adar Poonawalla had recently said. Besides this, Bharat Biotech's Covaxin is India's indigenous vaccine and is being developed in collaboration with the ICMR's National Institute of Virology. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility SEE ALSO: <a href="https://www.businessinsider.in/personal-finance/income-tax/news/income-tax-returns-filing-deadline-extended-to-january-10/articleshow/80029154.cms">Relief for taxpayers: Deadline to file income tax returns extended further to January 10</a> <a href="https://www.businessinsider.in/science/health/news/uk-approves-oxford-astrazeneca-covid-19-vaccine-for-emergency-use/articleshow/80023778.cms">UK approves Oxford-AstraZeneca COVID-19 vaccine</a> <a href="https://www.businessinsider.in/tech/apps/news/google-is-testing-a-shortcut-feature-for-tiktok-and-instagram-videos/articleshow/80021865.cms">Google is testing a shortcut feature for TikTok and Instagram videos</a>.

India continues to mull over SII and Bharat Biotech's COVID-19 vaccine candidates

Sydney, An Australian-developed Covid-19 vaccine has shown promising results in pre-clinical testing, raising hopes for its potential effectiveness and manufacturability. <keyword id="1408223" type="COMPANY" weightage="20" keywordseo="The-University-of-Queensland">The University of Queensland</keyword> (UQ) released detailed results of animal trials of its vaccine candidate on Tuesday to <keyword id="9826740" type="COMPANY" weightage="20" keywordseo="the-international-society-for-vaccines">the International Society for Vaccines</keyword>, <keyword id="106387" type="COMPANY" weightage="20" keywordseo="Xinhua-news-agency">Xinhua news agency</keyword> reported. UQ's "Molecular Clamp" vaccine works by locking on to the normally unstable, perfusion proteins on the surface of the virus, allowing the body's immune system to respond more effectively. "The neutralizing immune response created by our molecular clamp vaccine in animal models was better than the average level of antibodies found in patients who have recovered from Covid-19," Project co-leader Associate Professor Keith Chappell said. Phase 1 human trials for the drug commenced in Australia in July, prior to the current pre-clinical trial results being made public. Chappell said if everything proceeded as planned, large-scale manufacturing efficacy assessments could move ahead before the end of the year. "One of the big challenges in the development of vaccines is the ability to produce them at sufficient scale for widespread use," Chappell explained. In June, UQ revealed an agreement with Australian biotechnology giant CSL to locally manufacture millions of doses of the vaccine should it continue to prove viable throughout the rest of the trial process. Queensland Innovation Minister Kate Jones said a vaccine was vital for putting an end to the pandemic and the team from UQ were committed to sharing their data and comparing it to the international reference standard. "From the outset we've been clear that we are racing against the virus and not against other projects, and now more than ever it is important for the scientific world to work together," Jones said.

Australian Covid-19 vaccine has shown promising results in pre-clinical testing

As Indian firms scramble to develop a <keyword id="24209" type="PERSON" weightage="20" keywordseo="vaccine">vaccine</keyword> for <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword>, experts feel that research in the country is still at a nascent stage and any concrete breakthrough is not likely within a year. The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 3,700 lives with more than 1,25,000 cases in the country. PM CARES Fund Trust has decided to allocate Rs 100 crore for support to <keyword id="9276957" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine-development-efforts">coronavirus vaccine development efforts</keyword>. Referring to a vaccine to fight the virus, a PMO statement had said that it is the most pressing need and Indian academia, start-ups and industry have come together in cutting-edge vaccine design and development. The Department of Biotechnology has been made a central coordination agency to identify pathways for vaccine development. Naming the Indian firms working on vaccines for COVID-19, Gagandeep Kang, executive director of the Translational Health Science and Technology Institute, Faridabad, had said last month that while <keyword id="72130" type="COMPANY" weightage="20" keywordseo="Zydus-Cadila">Zydus Cadila</keyword> is working on two vaccines, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax are developing one vaccine each. The WHO has listed Serum Institute of India, Zydus Cadila, Indian Immunologicals Limited and Bharat Biotech from India among the firms involved in developing a vaccine. Leading virologist Shahid Jameel said India's vaccine manufacturing capacity is quite remarkable and at least three Indian companies - Serum Institute, Bharat Biotech and Biologicals E are at the forefont, working with international partners to manufacture a vaccine for COVID-19. "Research on a COVID vaccine in India is at a very early stage of development and any candidates are likely to reach animal trials only by the end of the year," he told . However, Indian vaccine companies have a lot of capacity and expertise, and are likely to play a significant role in bringing new COVID-19 vaccines to the market. This experience is important for institutions, industry and regulators to work together, and prepare for the future, said Jameel, a Shanti Swarup Bhatnagar Prize winner for Science and Technology and the current Chief Executive Officer of Wellcome Trust/Department of Biotechnology's India Alliance. CSIR-Centre for Cellular &amp; Molecular Biology (CCMB) Director Rakesh Mishra said, "From what we know, we are not at an advanced stage of vaccine development at the moment." "There are lots of ideas and companies initiating vaccine development process but there is nothing on trial in terms of vaccine candidates," he told . There are many efforts going on with different approaches like somebody wants to use the whole virus or a particular protein so there are multiple processes being deployed, he said. "Many Indian companies are collaborating with foreign institutions.Other countries are at much advanced stage than us. Some are going into third stage trials. There is no company testing vaccine in India yet and they are in the pre-clinical stage of preparation," he said. India is quite behind because of a number of reasons like the coronavirus came to India two-three months later so "we did not have the (inactivated) virus to test or even the urgency", Mishra said, adding that the Chinese and US are quite ahead in the vaccine development. "If a comparison has to be made we are well behind international efforts," he said. The novel coronavirus strain was isolated and characterised at the Indian Council of Medical Research's National Institute of Virology, Pune, and the vaccine candidate has been transferred to Bharat Biotech International Limited (BBIL) to develop a fully indigenous vaccine for COVID-19. "Once the vaccine is ready it will go for animal trials to be followed by human clinical trials to assess its safety and efficacy which will take at least one year," a senior <keyword id="6364396" type="UNKNOWN" weightage="20" keywordseo="ICMR">ICMR</keyword> official told . The BBIL is working towards developing killed virus vaccine which usually provides good immunogenicity, the official said, adding that by entering the body it will create antibody against the infection. The polio drops which are given to children have live attenuated virus, while the polio injection contains killed virus, the official said explaining the different approaches used in developing a vaccine. "The BBIL is continuously working in this direction and as soon as they get the right formulation they will move towards animal challenge studies followed by human clinical trials," the official said. Kang, in a webinar held by India Alliance, said there are two separate aspects that relates to vaccines of COVID-19, one is to use existing products and the second is to see if new vaccines can be made. "In terms of projects to develop vaccines there are around 90 plus projects around the world that have initiated to develop new vaccines which use different kinds of technologies. Some are using old technologies like make an inactivated virus and spike protein and other using new technologies that allow you to respond rapidly like using messenger RNA vaccines," Kang said. Every new technology is being applied for making COVID-19 vacines, he said. The Indian firms along with their foreign collaborators are racing against time to develop a vaccine against COVID-19 with over 52 lakh cases and over 3.35 lakh fatalities across the globe. UZM/PLB/ASK ZMN

You Searched For "COVID 19 vacine" and got 4 results

India may consider reducing the gap between second dose and the booster dose of COVID-19 for those travelling abroad

Vaamanaa Sethi

India continues to mull over SII and Bharat Biotech's COVID-19 vaccine candidates

IANS

Australian Covid-19 vaccine has shown promising results in pre-clinical testing

IANS

COVID-19 vaccine development at early stage in India; breakthrough unlikely within a year, say experts

PTI

Popular Keywords

Buying Guides